Management of Hypertension in CAKUT: Protective Factor for CKD

Patients with congenital kidney and urinary tract abnormalities (CAKUT) will often develop end-stage renal disease at some point and the need for renal replacement therapy is associated with high rates of morbidity and mortality. Hence, efforts to slow the progression of the disease are essential. H...

Full description

Bibliographic Details
Main Authors: Marina M. Gabriele, Paulo C. Koch Nogueira
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fped.2019.00222/full
_version_ 1818297232198205440
author Marina M. Gabriele
Paulo C. Koch Nogueira
author_facet Marina M. Gabriele
Paulo C. Koch Nogueira
author_sort Marina M. Gabriele
collection DOAJ
description Patients with congenital kidney and urinary tract abnormalities (CAKUT) will often develop end-stage renal disease at some point and the need for renal replacement therapy is associated with high rates of morbidity and mortality. Hence, efforts to slow the progression of the disease are essential. Hypertension has been proven to be an independent risk factor for faster decline of glomerular filtration rate in renal patients, but studies involving only children with CAKUT are scarce. We performed a literature review to explore the association of hypertension with faster chronic kidney disease progression in children with CAKUT and also treatment options in this condition. A recent study reported an annual decline in GFR of 1.8 ml/min/1.73 m2 among hypertensive patients with non-glomerular CKD, compared with 0.8 ml/min/1.73 m2 in normotensive children. A multicenter prospective cohort in Brazil showed that a 1-unit increase in systolic blood pressure Z-score was associated with a 1.5-fold higher risk of disease progression. Since renin-angiotensin-aldosterone system activation is the most important mechanism of hypertension in these children, the first-line therapy involves the use of inhibitors of this axis, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers type I, which also promote an anti-fibrotic effect. Recent studies have shown a good safety profile for use in patients with chronic kidney disease and also in those with solitary kidneys. Hypertension is an independent risk factor for kidney disease progression and should be promptly managed for renal protection, especially among patients with CAKUT, the primary cause of chronic kidney disease in the pediatric population.
first_indexed 2024-12-13T04:16:09Z
format Article
id doaj.art-025988f818ba40e790c4546cf2cd8986
institution Directory Open Access Journal
issn 2296-2360
language English
last_indexed 2024-12-13T04:16:09Z
publishDate 2019-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pediatrics
spelling doaj.art-025988f818ba40e790c4546cf2cd89862022-12-21T23:59:53ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602019-06-01710.3389/fped.2019.00222440701Management of Hypertension in CAKUT: Protective Factor for CKDMarina M. Gabriele0Paulo C. Koch Nogueira1Pediatric Nephrology Department, Instituto da Criança Hospital das Clínicas, University of São Paulo Medical School, São Paulo, BrazilPediatric Nephrology Department, UNIFESP–Escola Paulista de Medicina and Samaritano Hospital of São Paulo, São Paulo, BrazilPatients with congenital kidney and urinary tract abnormalities (CAKUT) will often develop end-stage renal disease at some point and the need for renal replacement therapy is associated with high rates of morbidity and mortality. Hence, efforts to slow the progression of the disease are essential. Hypertension has been proven to be an independent risk factor for faster decline of glomerular filtration rate in renal patients, but studies involving only children with CAKUT are scarce. We performed a literature review to explore the association of hypertension with faster chronic kidney disease progression in children with CAKUT and also treatment options in this condition. A recent study reported an annual decline in GFR of 1.8 ml/min/1.73 m2 among hypertensive patients with non-glomerular CKD, compared with 0.8 ml/min/1.73 m2 in normotensive children. A multicenter prospective cohort in Brazil showed that a 1-unit increase in systolic blood pressure Z-score was associated with a 1.5-fold higher risk of disease progression. Since renin-angiotensin-aldosterone system activation is the most important mechanism of hypertension in these children, the first-line therapy involves the use of inhibitors of this axis, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers type I, which also promote an anti-fibrotic effect. Recent studies have shown a good safety profile for use in patients with chronic kidney disease and also in those with solitary kidneys. Hypertension is an independent risk factor for kidney disease progression and should be promptly managed for renal protection, especially among patients with CAKUT, the primary cause of chronic kidney disease in the pediatric population.https://www.frontiersin.org/article/10.3389/fped.2019.00222/fullCAKUTchronic kidney disease (CKD)hypertensionrenal disease progressionrisk factorchildren
spellingShingle Marina M. Gabriele
Paulo C. Koch Nogueira
Management of Hypertension in CAKUT: Protective Factor for CKD
Frontiers in Pediatrics
CAKUT
chronic kidney disease (CKD)
hypertension
renal disease progression
risk factor
children
title Management of Hypertension in CAKUT: Protective Factor for CKD
title_full Management of Hypertension in CAKUT: Protective Factor for CKD
title_fullStr Management of Hypertension in CAKUT: Protective Factor for CKD
title_full_unstemmed Management of Hypertension in CAKUT: Protective Factor for CKD
title_short Management of Hypertension in CAKUT: Protective Factor for CKD
title_sort management of hypertension in cakut protective factor for ckd
topic CAKUT
chronic kidney disease (CKD)
hypertension
renal disease progression
risk factor
children
url https://www.frontiersin.org/article/10.3389/fped.2019.00222/full
work_keys_str_mv AT marinamgabriele managementofhypertensionincakutprotectivefactorforckd
AT paulockochnogueira managementofhypertensionincakutprotectivefactorforckd